Solid Biosciences Inc. Common Stock

Day range

$5.74 – $6.09

Open

$6.00

Prev close

$5.92

Volume

1.07M

Market cap

$634.77M

Shares out

107.23M

P/E

—

P/S

—

P/B

1.70

P/FCF

—

ROE

-55.4%

ROA

-49.2%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Public offeringAug 6, 2026

  On August 6, 2026, Solid Biosciences Inc. (the "Company") filed a prospectus supplement (the "Prospectus Supplement") under the Company's universal shelf registration statement on Form S-3 relating to the offer and sale of a total of up to $200.0 million of shares of the Company's common stock, par value $0.001 per share (the "Shares"), pursuant to an Amended and Restated Sales Agreement, dated March 13, 2024, with Jefferies LLC (the "Sales Agreement").

• Annual meeting resultsJun 10, 2026

  Solid Biosciences Inc. held its Annual Meeting of Stockholders on June 10, 2026 to consider and vote upon the matters listed below. The Company's stockholders elected Clare Kahn, Adam Stone and Lynne Sullivan as Class II directors to serve until the 2029 Annual Meeting of Stockholders.

• Director departureApr 10, 2026

  Effective at 4:00 p.m., Eastern Time, on April 10, 2026, Ilan Ganot, a member of the Board who was serving in Class III (which class will be up for election at the Company's 2027 Annual Meeting of Stockholders), resigned from the Board.

• Clinical trial resultsMar 12, 2026

  On March 11, 2026, the Company announced positive new interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, a Phase 1/2 first-in-human, open-label, single-dose, multicenter trial designed to evaluate the safety, tolerability and efficacy of SGT-003 in pediatric participants with Duchenne muscular dystrophy. SGT-003 has been generally well tolerated in the 40 participants dosed as of March 11, 2026.

• Private placementMar 6, 2026

  On March 6, 2026, Solid Biosciences Inc., a Delaware corporation (the "Company"), entered into a securities purchase agreement (the "Securities Purchase Agreement") with certain institutional accredited investors (the "Investors"), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 14,973,257 shares of the Company's common stock, par value $0.001 per share (the "Shares"), at a price of $5.61 per share, and, to investors who so choose in lieu of Shares, pre-funded warrants to purchase 27,807,482 shares of the Company's common stock (the "Pre-Funded Warrants"), at a price of $5.609 per Pre-Funded Warrant.

Days to cover

7.7

Short interest

12.73M

Avg volume

1.66M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
  positiveGlobeNewswire Inc.· May 26, 2026
• Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
  positiveGlobeNewswire Inc.· Dec 16, 2025
• Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
  positiveGlobeNewswire Inc.· Dec 1, 2025
• Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101
  positiveGlobeNewswire Inc.· Nov 17, 2025
• Solid Biosciences to Participate at Upcoming Investor Conferences
  positiveGlobeNewswire Inc.· Nov 11, 2025